Prescription medicine
Diflorasone Brand names: Psorcon; first approved as Florone
Diflorasone (Psorcon) is a prescription medicine with an FDA approval on record since 1977. FDA's NDC Directory lists it from 2 generic labelers, and pharmacies paid $2.05 per gram (Diflorasone 0.05% ointment) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the diflorasone FDA label on DailyMed (effective May 2, 2023, Rising Pharma Holdings, Inc.); the NDA 17741 record on Drugs@FDA; every diflorasone label on DailyMed.
Highlights of the record
FDA label of May 2, 2023; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageTopical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Forms and strengths
- 0.5 mg/g
- 5 mg/g
Ointment; cream.
On the market
- Earliest approval on file
- September 14, 1977 Florone, Pfizer; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 8 first March 30, 1998; 5 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 2 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $2.05 per gram Diflorasone 0.05% ointment
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 4 since 2021 0 Class I among all firms' recalls; latest June 24, 2024
- FAERS reports
- 188 through July 30, 2026
What is diflorasone used for?
From the label: indications and usageTopical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
FDA pharmacologic class: Corticosteroid.
Source: FDA drug label (Diflorasone Diacetate), Rising Pharma Holdings, Inc., effective May 2, 2023 (SPL set 23eb27a4-157f-4eb5-a390-37586710808f), via openFDA; the full label on DailyMed
Is there a generic for diflorasone (Psorcon)?
The FDA approved the first generic diflorasone on March 30, 1998. 8 generic applications are approved; 5 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists diflorasone from 2 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1977 earliest approval on file
- 1998 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for diflorasone (Psorcon)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.05 per gram (Diflorasone 0.05% ointment), up 34% from $1.53 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Diflorasone 0.05% ointment (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Diflorasone 0.05% cream | Generic | $8.28 per gram | n/a | +38% |
| Diflorasone 0.05% ointment | Generic | $2.05 per gram | n/a | +34% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has diflorasone been recalled?
The FDA's Enforcement Report lists 4 recalls naming diflorasone since 2021: 0 Class I (the most serious), 3 Class II, 1 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| June 24, 2024 | Class III | Rising Pharma Holding, Inc. | Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit. |
| March 15, 2022 | Class II | Teligent Pharma, Inc. | cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program. |
| May 14, 2021 | Class II | Teligent Pharma, Inc. | Presence of Foreign Substance: Foreign particles observed during routine stability testing. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What do FAERS reports show for diflorasone?
The FDA Adverse Event Reporting System holds 188 reports that list diflorasone among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 11 are coded as a death and 73 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other corticosteroids
- the pharmacologic class, with prices and generics
- Diflorasone side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other